The Frictionless Trap

As CEO Noor Siddiqui pitches genetic "trust funds" in Austin, a new technological convergence promises to edit out the risks that make us human.

[Speaker 1]: It was a dinner party in Austin, back in July of last year. The aesthetic was very specific-lots of pastels, floral arrangements, very "wellness." And the guests were these elite, high-powered women, mostly from the tech world. They were all wearing these matching hats that just said, in soft lettering: BABIES. [Speaker 2]: It looks like a baby shower, but it’s not. [Speaker 1]: No. It was a launch event for a company called Orchid. And the conversation wasn’t about nurseries or strollers. It was about data deletion. Specifically, using whole-genome sequencing to screen embryos and "delete" the risk of chronic disease before a child is even conceived. [Speaker 2]: And the way this was pitched wasn’t as a medical procedure. It was pitched as a moral imperative. The CEO, Noor Siddiqui, has this line she uses: she calls a healthy genome a "trust fund" for the child’s future. [Speaker 1]: Right. And while those women were discussing how to scrub biological friction from their children’s lives, just a few miles away, another group of developers was finalizing a device to scrub social friction from our own lives. [Speaker 2]: The "Friend" pendant. [Speaker 1]: Exactly. Today, we’re looking at how these two technologies converged this month to offer us a friction-free existence. One edits out the risk of disease; the other edits out the risk of rejection. [Speaker 2]: But psychologists are warning about a concept called *Technological Folie à Deux*-a "madness of two." [Speaker 1]: We’re going to find out if we’re solving suffering, or if we’re just building a really comfortable trap. [Speaker 2]: It’s Monday, January 26, 2026, and you’re listening to The Angle. [Speaker 1]: So to understand why we’re talking about this right now, we have to look at the calendar. We are three weeks into a massive shift in American healthcare that started on New Year’s Day. [Speaker 2]: Right. On January 1st, California Senate Bill 729 went into effect. [Speaker 1]: And this is a big deal. For years, IVF and genetic screening were luxury goods-services for the wealthy. But SB 729 mandates that large group health plans in California cover IVF. It opens the door for millions of people to access reproductive technology that was previously out of reach. [Speaker 2]: It turns a boutique bio-hack into a potential standard of care. And that matters because of what companies like Orchid are offering. This isn’t the old school genetic screening. [Speaker 1]: Yeah, break that down. Because people have been screening embryos for decades. [Speaker 2]: They have, but that was mostly PGT-M. That’s looking for a specific, single-gene mutation. Like, if you know you carry the gene for Cystic Fibrosis, you check the embryo for that one broken switch. It’s a yes or no question. [Speaker 1]: What we’re seeing now is PGT-P. The "P" stands for Polygenic. [Speaker 2]: Exactly. Instead of looking for one broken switch, they sequence the entire genome of the embryo. They look at millions of markers and compare them against massive population databases. Then, they give that embryo a "risk score" percentile for complex conditions. Heart disease, diabetes, schizophrenia, certain cancers. [Speaker 1]: So practically, you’re standing in a clinic, and you have five viable embryos. And the doctor doesn't just say "these look healthy." They give you a report card. Embryo A has a top-tier score for heart health but is in the 40th percentile for breast cancer risk. Embryo B is the opposite. And you have to choose. [Speaker 2]: Orchid charges about $2,500 per embryo for this. And the…